FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016122617> ?p ?o ?g. }

• W2016122617 endingPage "936" @default.
• W2016122617 startingPage "911" @default.
• W2016122617 abstract "Objective:This open-label, phase 3b study evaluated the effectiveness and tolerability of tapentadol prolonged release and tapentadol immediate release (for acute pain episodes) for severe, chronic low back pain with or without a neuropathic pain component that was inadequately managed in patients taking World Health Organization (WHO) Step I or II analgesics or who were not regularly treated with analgesics.Research design and methods:Average baseline pain intensity was greater than 5 (11-point numerical rating scale-3 [NRS-3; 3-day average pain intensity]) with WHO Step I or II analgesics and greater than 6 with no regular analgesic regimen. WHO Step II analgesics were discontinued before starting study treatment; WHO Step I analgesics or co-analgesics were continued at the same dose. Patients received tapentadol prolonged release (50–250 mg bid) during a 5-week titration and 7-week maintenance period. Tapentadol immediate release was permitted for acute pain episodes (tapentadol prolonged release and immediate release maximum combined dose, ≤500 mg/day). The painDETECT questionnaire was used to define subsets of patients based on the probability of a neuropathic pain component to their low back pain as ‘negative’, ‘unclear’, or ‘positive’.Clinical trial registration: NCT00983385.Main outcome measure:The primary endpoint was the change from baseline to week 6 in average pain intensity (NRS-3), using the last observation carried forward to impute missing scores.Results:In the painDETECT negative (n = 49) and unclear/positive (n = 126) subsets, respectively, mean (SD) changes in pain intensity from baseline to week 6 were −2.4 (2.18) and −3.0 (2.07; both p < 0.0001). Among patients who had not received prior WHO Step II treatment, lower doses of tapentadol prolonged release were generally required with increasing likelihood of a neuropathic pain component. Based on the painDETECT questionnaire and the Neuropathic Pain Symptom Inventory (NPSI), tapentadol prolonged release treatment was also associated with significant improvements in neuropathic pain symptoms, with decreases in the number of pain attacks and the duration of spontaneous pain in the last 24 hours in patients with low back pain with a neuropathic pain component (painDETECT unclear or positive score at baseline or screening). The most common treatment-emergent adverse events (incidence ≥10%, n = 176) were nausea, dizziness, headache, dry mouth, fatigue, constipation, diarrhea, nasopharyngitis, and somnolence.Conclusions:Tapentadol prolonged release was well tolerated and effective for managing severe, chronic low back pain with or without a neuropathic pain component." @default.
• W2016122617 created "2016-06-24" @default.
• W2016122617 creator A5001726013 @default.
• W2016122617 creator A5001729452 @default.
• W2016122617 creator A5024020276 @default.
• W2016122617 creator A5024298888 @default.
• W2016122617 creator A5027284020 @default.
• W2016122617 creator A5049547783 @default.
• W2016122617 creator A5063972403 @default.
• W2016122617 creator A5064397683 @default.
• W2016122617 creator A5065679643 @default.
• W2016122617 creator A5089968471 @default.
• W2016122617 date "2012-05-09" @default.
• W2016122617 modified "2023-10-16" @default.
• W2016122617 title "Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study" @default.
• W2016122617 cites W1164896577 @default.
• W2016122617 cites W1562338169 @default.
• W2016122617 cites W1980190867 @default.
• W2016122617 cites W1987138256 @default.
• W2016122617 cites W1992314523 @default.
• W2016122617 cites W2003069609 @default.
• W2016122617 cites W2022054436 @default.
• W2016122617 cites W2026275728 @default.
• W2016122617 cites W2028140282 @default.
• W2016122617 cites W2033766978 @default.
• W2016122617 cites W2036933778 @default.
• W2016122617 cites W2058016317 @default.
• W2016122617 cites W2060855217 @default.
• W2016122617 cites W2064152721 @default.
• W2016122617 cites W2067381900 @default.
• W2016122617 cites W2067689995 @default.
• W2016122617 cites W2069426265 @default.
• W2016122617 cites W2096716094 @default.
• W2016122617 cites W2113933207 @default.
• W2016122617 cites W2116201094 @default.
• W2016122617 cites W2128412489 @default.
• W2016122617 cites W2129860136 @default.
• W2016122617 cites W2132309748 @default.
• W2016122617 cites W2136743000 @default.
• W2016122617 cites W2138407894 @default.
• W2016122617 cites W2138446311 @default.
• W2016122617 cites W2144003721 @default.
• W2016122617 cites W2149599746 @default.
• W2016122617 cites W2152966475 @default.
• W2016122617 cites W2154693681 @default.
• W2016122617 cites W2155412494 @default.
• W2016122617 cites W2156173888 @default.
• W2016122617 cites W2157999436 @default.
• W2016122617 cites W2158017724 @default.
• W2016122617 cites W2171369299 @default.
• W2016122617 cites W3194956376 @default.
• W2016122617 cites W4247185122 @default.
• W2016122617 cites W4255978203 @default.
• W2016122617 doi "https://doi.org/10.1185/03007995.2012.679254" @default.
• W2016122617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22443293" @default.
• W2016122617 hasPublicationYear "2012" @default.
• W2016122617 type Work @default.
• W2016122617 sameAs 2016122617 @default.
• W2016122617 citedByCount "72" @default.
• W2016122617 countsByYear W20161226172012 @default.
• W2016122617 countsByYear W20161226172013 @default.
• W2016122617 countsByYear W20161226172014 @default.
• W2016122617 countsByYear W20161226172015 @default.
• W2016122617 countsByYear W20161226172016 @default.
• W2016122617 countsByYear W20161226172017 @default.
• W2016122617 countsByYear W20161226172018 @default.
• W2016122617 countsByYear W20161226172019 @default.
• W2016122617 countsByYear W20161226172020 @default.
• W2016122617 countsByYear W20161226172021 @default.
• W2016122617 countsByYear W20161226172022 @default.
• W2016122617 countsByYear W20161226172023 @default.
• W2016122617 crossrefType "journal-article" @default.
• W2016122617 hasAuthorship W2016122617A5001726013 @default.
• W2016122617 hasAuthorship W2016122617A5001729452 @default.
• W2016122617 hasAuthorship W2016122617A5024020276 @default.
• W2016122617 hasAuthorship W2016122617A5024298888 @default.
• W2016122617 hasAuthorship W2016122617A5027284020 @default.
• W2016122617 hasAuthorship W2016122617A5049547783 @default.
• W2016122617 hasAuthorship W2016122617A5063972403 @default.
• W2016122617 hasAuthorship W2016122617A5064397683 @default.
• W2016122617 hasAuthorship W2016122617A5065679643 @default.
• W2016122617 hasAuthorship W2016122617A5089968471 @default.
• W2016122617 hasConcept C126322002 @default.
• W2016122617 hasConcept C141071460 @default.
• W2016122617 hasConcept C142724271 @default.
• W2016122617 hasConcept C170493617 @default.
• W2016122617 hasConcept C1862650 @default.
• W2016122617 hasConcept C197934379 @default.
• W2016122617 hasConcept C203092338 @default.
• W2016122617 hasConcept C204787440 @default.
• W2016122617 hasConcept C2777107010 @default.
• W2016122617 hasConcept C2778375690 @default.
• W2016122617 hasConcept C2780505013 @default.
• W2016122617 hasConcept C2780820201 @default.
• W2016122617 hasConcept C2780907711 @default.
• W2016122617 hasConcept C2781063702 @default.
• W2016122617 hasConcept C2781118164 @default.
• W2016122617 hasConcept C2781413609 @default.

• next